At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study
Sign Up to like & getrecommendations! Published in 2021 at "Depression and Anxiety"
DOI: 10.1002/da.23138
Abstract: It is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real‐world setting and the effects of the medication. read more here.
Keywords: depression; baseline patients; higher burden; patients treated ... See more keywords